title: A successfully treated inflammatory myofibroblastic tumor of the mandible with long-term follow-up and review of the literature.
abstract: Inflammatory myofibroblastic tumor (IMT) of the oral cavity is an extremely rare clinical and pathological disease entity. It was originally described in the lung but has recently been reported in various anatomic sites. We report such a case of inflammatory myofibroblastic tumor of the mandible in a 14-year-old girl. The patient presented with an aggressive ulcerative soft tissue mass of 3 months duration in the mandibular molar gingiva. Histologically, the lesion was composed of fibroblastic or myofibroblastic spindle cell proliferations with infiltrative margins in an inflammatory background. Immunohistochemically, the fibroblastic or myofibroblastic spindle cells were positive for vimentin, α-smooth muscle actin, and Ki-67 (MIB-1) but negative for desmin, pan-cytokeratin, S-100 protein, CD34, CD68, CD99, bcl-2, β-catenin, estrogen receptor, progesterone receptor, ALK-1, and p53. These spindle cells were focally and weakly Ki-67- (MIB-1-) positive. The MIB-1 labeling index was 5%. The results of in situ hybridization for Epstein-Barr virus-encoded-RNA were negative. The ratio of IgG4+/IgG+ plasma cells was about 10%. A pathological diagnosis of inflammatory myofibroblastic tumor was made. The postoperative course was uneventful, and the patient has had no recurrence in the 10-year follow-up period. Although no evidence of oral inflammatory myofibroblastic tumor recurrence or malignant transformation has been reported, it has been observed that in inflammatory myofibroblastic tumors of other regions, a prolonged follow-up is necessary after surgical resection. No other case of an IMT patient under 20 years of age has appeared in either the English or the Japanese literature.
authors.affiliation: Department of Oral and Maxillofacial Surgery, Tokyo Medical University Hospital, 6-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan. tsatomi@tokyo-med.ac.jp
authors.forename: Takafumi
authors.initials: T
authors.lastname: Satomi
authors.forename: Masato
authors.initials: M
authors.lastname: Watanabe
authors.forename: Jun
authors.initials: J
authors.lastname: Matsubayashi
authors.forename: Toshitaka
authors.initials: T
authors.lastname: Nagao
authors.forename: Hiroshige
authors.initials: H
authors.lastname: Chiba
mesh_terms: D000199:Actins / Q000032:analysis; D000293:Adolescent; D014408:Biomarkers, Tumor / Q000032:analysis; D005260:Female; D006801:Humans; D019394:Ki-67 Antigen / Q000032:analysis; D008339:Mandibular Neoplasms / Q000473:pathology* / Q000601:surgery*; D009379:Neoplasms, Muscle Tissue / Q000473:pathology* / Q000601:surgery*; D016896:Treatment Outcome; D014746:Vimentin / Q000032:analysis
chemical_list: C541116:ACTA2 protein, human; D000199:Actins; D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen; D014746:Vimentin